

# Dirk M<sup>1</sup>/<sub>4</sub>ller-Wieland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6610252/publications.pdf>

Version: 2024-02-01

56  
papers

2,349  
citations

279487

23  
h-index

223531

46  
g-index

68  
all docs

68  
docs citations

68  
times ranked

3575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition, Classification and Diagnosis of Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S1-S7.	0.6	263
2	Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. <i>Respiratory Medicine</i> , 2020, 174, 106197.	1.3	235
3	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	1.0	142
4	Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. <i>PLoS ONE</i> , 2012, 7, e31812.	1.1	141
5	MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro. <i>Journal of Biological Chemistry</i> , 2000, 275, 33302-33307.	1.6	139
6	SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I. <i>Journal of Biological Chemistry</i> , 1996, 271, 7128-7133.	1.6	137
7	Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver. <i>Diabetes</i> , 2017, 66, 2241-2253.	0.3	124
8	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY 4 INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	2.2	105
9	Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo. <i>Journal of Biological Chemistry</i> , 2004, 279, 22404-22411.	1.6	99
10	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. <i>EPMA Journal</i> , 2019, 10, 445-464.	3.3	96
11	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY 4 DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
12	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as addition to metformin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2598-2607.	2.2	48
13	Peroxisomes compensate hepatic lipid overflow in mice with fatty liver. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 965-976.	1.2	43
14	Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity. <i>PLoS ONE</i> , 2012, 7, e32609.	1.1	42
15	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.	0.6	38
16	Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. <i>Atherosclerosis</i> , 2010, 213, 156-165.	0.4	36
17	Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. <i>Scientific Reports</i> , 2021, 11, 2256.	1.6	35
18	Insulin Resistance and Vulnerability to Cardiac Ischemia. <i>Diabetes</i> , 2018, 67, 2695-2702.	0.3	31

#	ARTICLE	IF	CITATIONS
19	Inactivation of SREBP-1a Phosphorylation Prevents Fatty Liver Disease in Mice: Identification of Related Signaling Pathways by Gene Expression Profiles in Liver and Proteomes of Peroxisomes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 980.	1.8	30
20	Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolipidemia. <i>Atherosclerosis</i> , 2011, 218, 134-143.	0.4	29
21	The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2671-2684.	1.8	28
22	Definition, Classification and Diagnosis of Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S1-S8.	0.6	28
23	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 149.	2.7	27
24	Differential glycaemic control with basal insulin glargine 300 $\mu\text{g/mL}$ versus degludec 100 $\mu\text{g/mL}$ according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1369-1377.	2.2	26
25	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	2.7	25
26	Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 248.	1.8	23
27	Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4144.	1.8	22
28	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22
29	So close and yet so far: mitochondria and peroxisomes are one but with specific talents. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 126-135.	1.0	21
30	Six Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5861.	1.2	20
31	Lipodystrophies – Disorders of the Fatty Tissue. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8778.	1.8	18
32	Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 9895.	1.6	18
33	Adipokine Signatures in Obese Mouse Models Reflect Adipose Tissue Health and Are Associated with Serum Lipid Composition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2559.	1.8	17
34	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1632-1641.	2.2	15
35	Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany. <i>Hormone and Metabolic Research</i> , 2018, 50, 728-734.	0.7	14
36	Reliable Detection of Atrial Fibrillation with a Medical Wearable during Inpatient Conditions. <i>Sensors</i> , 2020, 20, 5517.	2.1	13

#	ARTICLE	IF	CITATIONS
37	Survey to estimate the prevalence of type 2 diabetes mellitus in hospital patients in Germany by systematic HbA1c measurement upon admission. <i>International Journal of Clinical Practice</i> , 2018, 72, e13273.	0.8	11
38	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674.	0.8	9
39	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. <i>Advances in Therapy</i> , 2020, 37, 3863-3877.	1.3	7
40	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0246182.	1.1	7
41	PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2019, 21, 40.	2.0	6
42	Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis. <i>Diabetes Therapy</i> , 2021, 12, 1073-1097.	1.2	5
43	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	0.6	5
44	Definition, classification and diagnostics of diabetes mellitus. <i>Laboratoriums Medizin</i> , 2018, 42, 73-79.	0.1	4
45	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
46	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S102-S104.	0.6	4
47	Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. <i>Diabetes Therapy</i> , 2021, 12, 1159-1174.	1.2	4
48	Association between copy-number variation on metabolic phenotypes and HDL-C levels in patients with polycystic ovary syndrome. <i>Molecular Biology Reports</i> , 2017, 44, 51-61.	1.0	3
49	Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis. <i>Diabetes Therapy</i> , 2021, , .	1.2	3
50	Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100126.	1.0	3
51	Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). <i>Archives of Physiology and Biochemistry</i> , 2016, 122, 266-280.	1.0	2
52	Development of the Metabolic Syndrome: Study Design and Baseline Data of the Lufthansa Prevention Study (LUPS), A Prospective Observational Cohort Survey. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 777-787.	0.6	2
53	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	0.6	1
54	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S97-S101.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Dyslipidämien: Aktuelles Lipid-Management. , 0, , .		0
56	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, , .	0.6	0